ELRIG Drug Discovery 2026 has ended. This guide stays up as the record of who was there. Next: ELRIG DD 2027, Oct 19–20, 2027 in Liverpool
Multi-omics at ELRIG Drug Discovery 2026
Oct 14–15, 2026 London, UK ~3k attendees Website
39 organizations at ELRIG Drug Discovery 2026 present work in multi-omics: 30 technology and service providers, 6 drug developers and 3 academic, government and non-profit bodies. Between them they bring 27 presentations to the program. Most represented: GSK (8 on the program), University College London (3 on the program), Imperial College London (2 on the program). As of Oct 8, 2026.
Format
Top represented
Showing 1–15 of 39 organizations
| Organization | ELRIG Drug Discovery 2026 Attendance |
|---|---|
GSK London, UK | ◆Partner |
Global biopharmaceutical company developing vaccines and specialty medicines in infectious disease, HIV, respiratory, immunology and oncology. | Booth Exhibiting at Booth CZ02 Wed, Oct 148:00am–7:00pmThu, Oct 158:00am–4:00pm Chair Wed Oct 14 11:15am–11:20am Track Chair - Engineering the cell microenvironment: Cell-based models for drug discovery How engineered cell surroundings, from three-dimensional cultures to immune-competent models, help lab assays better predict what happens in patients. Talk Wed Oct 14 11:20am–11:50am Talk Wed Oct 14 2:00pm–2:30pm Talk Wed Oct 14 2:00pm–2:30pm Talk Wed Oct 14 2:40pm–3:10pm Talk Wed Oct 14 5:30pm–6:30pm Early Career Professionals: Network Like A Boss Meeting other early career professionals in speed networking rounds to build the contacts a drug discovery career depends on. Panel Thu Oct 15 9:30am–10:15am Keynote Panel - 20 Years of Discovery: Lessons from the Past, Blueprints for the Next 20 What two decades of change in drug discovery, from high-throughput screening to AI design, teach about building the next generation of medicines. Talk Thu Oct 15 2:30pm–3:00pm |
University College London London, UK | |
Public research university in London. | Talk Wed Oct 14 3:45pm–4:15pm Talk Thu Oct 15 12:40pm–1:10pm |
Imperial College London London, UK | |
London research university in science, engineering, medicine and business. | Talk Thu Oct 15 11:55am–12:25pm Talk Thu Oct 15 3:00pm–3:30pm |
Tecan Männedorf, Switzerland | ◆Conference Partner |
Swiss maker of automated liquid handling and laboratory instruments for research, drug discovery and clinical diagnostics. | Booth Exhibiting at Booth B03, B04 Wed, Oct 148:00am–7:00pmThu, Oct 158:00am–4:00pm Talk Thu Oct 15 11:25am–11:55am The Biology Is Only as Good as the Workflow: Multiomics Strategies for Biomarker Discovery and Utilisation in Precision Medicine Why reading a patient's genes, proteins and metabolites together, with reliable automated sample handling, is needed to match drugs to individual biology. |
Develops small-molecule medicines based on targeted protein degradation. | Chair Thu Oct 15 10:50am–10:55am Track Chair - From multi-omics to clinical outcomes: Insights for drug development How much molecular data and how many participants early studies need, and which signals from large biological datasets can be trusted. |
Constructive Bio Cambridge, UK | |
Expands the genetic code to build proteins containing new-to-nature chemical building blocks for next-generation therapeutics. | Panel Thu Oct 15 9:30am–10:15am Keynote Panel - 20 Years of Discovery: Lessons from the Past, Blueprints for the Next 20 What two decades of change in drug discovery, from high-throughput screening to AI design, teach about building the next generation of medicines. |
Digital pathology service with a network of subspecialist pathologists, providing remote diagnostic reporting and pathology support for clinical trials. | Talk Thu Oct 15 2:30pm–3:00pm |
Moderna Cambridge, MA | |
mRNA medicines company with marketed vaccines and a pipeline spanning infectious disease, oncology and rare disease. | Chair Thu Oct 15 10:50am–10:55am Track Chair - From multi-omics to clinical outcomes: Insights for drug development How much molecular data and how many participants early studies need, and which signals from large biological datasets can be trusted. |
Molecular Partners Zurich, Switzerland | |
Clinical-stage biotech developing DARPin protein therapeutics. | Talk Thu Oct 15 10:55am–11:25am |
Omega Funds Boston, MA | |
Venture capital firm investing in life science and biotech companies. | Panel Thu Oct 15 9:30am–10:15am Keynote Panel - 20 Years of Discovery: Lessons from the Past, Blueprints for the Next 20 What two decades of change in drug discovery, from high-throughput screening to AI design, teach about building the next generation of medicines. |
Precision immunology start-up aiming to detect, monitor and treat autoimmune and other immune-driven inflammatory conditions earlier. | Panel Thu Oct 15 9:30am–10:15am Keynote Panel - 20 Years of Discovery: Lessons from the Past, Blueprints for the Next 20 What two decades of change in drug discovery, from high-throughput screening to AI design, teach about building the next generation of medicines. |
UK health research programme building a large volunteer cohort with health data and samples for research. | Panel Thu Oct 15 9:30am–10:15am Keynote Panel - 20 Years of Discovery: Lessons from the Past, Blueprints for the Next 20 What two decades of change in drug discovery, from high-throughput screening to AI design, teach about building the next generation of medicines. |
Propath Hereford, UK | |
Molecular pathology and histopathology CRO for biopharma, offering spatial proteomics and transcriptomics, multiplex imaging and image analysis for biomarker studies. | Talk Thu Oct 15 3:30pm–4:00pm |
Bio-Rad Hercules, California | |
Develops and sells life science research and clinical diagnostic products, including droplet digital PCR for translational and clinical work. | Booth Exhibiting at Booth C13, C28 Wed, Oct 148:00am–7:00pmThu, Oct 158:00am–4:00pm Talk Thu Oct 15 12:25pm–12:40pm Precision That Translates: ddPCR from Discovery to Clinic How droplet digital polymerase chain reaction counts molecules precisely enough to carry biomarker findings into clinical and manufacturing checks. |
Myllia Vienna, Austria | |
Runs CRISPR screens in primary human cells with single-cell RNA readouts, generating perturbation data for target discovery and AI models. | Booth Exhibiting at Booth F06 Wed, Oct 148:00am–7:00pmThu, Oct 158:00am–4:00pm Talk Wed Oct 14 2:30pm–2:35pm |
Instantly find 20 buyers in multi-omics
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ELRIG Drug Discovery 2026 by
Organization type
Topic
Exhibit hall
Everyone
Not affiliated with or endorsed by ELRIG. Submit a correction